Sarepta Therapeutics (SRPT) Hits New 1-Year High and Low After Analyst Upgrade

Sarepta Therapeutics (NASDAQ:SRPT) shares hit a new 52-week high and low during mid-day trading on Wednesday after Leerink Swann raised their price target on the stock from $88.00 to $121.00. Leerink Swann currently has an outperform rating on the stock. Sarepta Therapeutics traded as low as $95.67 and last traded at $94.81, with a volume of 42782 shares. The stock had previously closed at $92.22.

Several other research analysts have also recently issued reports on SRPT. Morgan Stanley raised their target price on shares of Sarepta Therapeutics from $87.00 to $91.00 and gave the stock an “equal weight” rating in a report on Friday, May 4th. Credit Suisse Group set a $92.00 price target on shares of Sarepta Therapeutics and gave the company a “buy” rating in a research report on Friday, May 4th. Oppenheimer lowered shares of Sarepta Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Friday, May 4th. JMP Securities restated an “outperform” rating and set a $90.00 price target (down previously from $95.00) on shares of Sarepta Therapeutics in a research report on Friday, May 4th. Finally, Royal Bank of Canada raised their price target on shares of Sarepta Therapeutics to $98.00 and gave the company a “positive” rating in a research report on Friday, May 4th. Five research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $86.88.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Principal Financial Group Inc. grew its position in shares of Sarepta Therapeutics by 2.7% in the first quarter. Principal Financial Group Inc. now owns 19,946 shares of the biotechnology company’s stock valued at $1,478,000 after purchasing an additional 530 shares during the period. Benchmark Capital Advisors grew its position in shares of Sarepta Therapeutics by 4.2% in the fourth quarter. Benchmark Capital Advisors now owns 21,250 shares of the biotechnology company’s stock valued at $1,182,000 after purchasing an additional 850 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Sarepta Therapeutics by 39.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,448 shares of the biotechnology company’s stock valued at $192,000 after purchasing an additional 977 shares during the period. LPL Financial LLC grew its position in shares of Sarepta Therapeutics by 8.8% in the first quarter. LPL Financial LLC now owns 12,579 shares of the biotechnology company’s stock valued at $932,000 after purchasing an additional 1,020 shares during the period. Finally, US Bancorp DE grew its position in shares of Sarepta Therapeutics by 35.0% in the fourth quarter. US Bancorp DE now owns 4,224 shares of the biotechnology company’s stock valued at $235,000 after purchasing an additional 1,095 shares during the period. Institutional investors and hedge funds own 85.21% of the company’s stock.

The stock has a market cap of $6.10 billion, a PE ratio of -57.29 and a beta of 1.34. The company has a current ratio of 13.37, a quick ratio of 12.28 and a debt-to-equity ratio of 0.55.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Thursday, May 3rd. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by ($0.23). Sarepta Therapeutics had a negative net margin of 83.88% and a negative return on equity of 24.68%. The company had revenue of $64.60 million during the quarter, compared to analyst estimates of $65.31 million. During the same quarter last year, the business earned ($0.57) EPS. The firm’s revenue for the quarter was up 295.3% compared to the same quarter last year. research analysts expect that Sarepta Therapeutics will post -1.79 earnings per share for the current fiscal year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply